eNewsWire

Online pharmacies should operate by giving whatever health concerns you have as patients. These providers should not focus on the profit you will get. Your health should not be put at risk.

It is for this reason that these pharmacies present products to you with all the pertinent details you should know. You are entitled to know facts about the formulation of these drugs. As for Lutein for eyes and Tamiflu swine flu treatment, here is a list of important information on these medications. Read more…

Actavis Group, the international generic pharmaceuticals company, launched Pantoprazole tablets in Germany, Ireland, and the Netherlands as the patent expired on 6 May. This is Actavis Group’s first own brand launch of this molecule.

In Germany and the Netherlands, the product was also launched by Actavis’ third party sales division’s (Medis’) customers at the same time. Earlier this year, Medis’ customers launched the product in Hungary and Poland.

Pantoprazole, a proton pump inhibitor (PPI), is used to treat acid-related stomach and throat problems, including acid reflux (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Pantoprazole Actavis is the generic equivalent of Wyeth’s Protonix®.

Pantoprazole Actavis is available in 20mg and 40mg tablets. The product was developed by Actavis R&D in Iceland, and manufactured by Actavis Malta.

IMS Health reported EU Brand sales of EUR1.1 bln in 2008. Read more…

Little Falls facility resumes production with FDA approval of critical pain solution

Reykjavik, Iceland, 17 April 2009 — Actavis Group, the international generic pharmaceuticals company, today announced the reintroduction by its subsidiary in the United States of Oxycodone 15 mg and 30 mg tablet products to pharmacies and customers. Oxycodone is the first product to be manufactured at Actavis’ Little Falls, NJ facility following a recently completed FDA inspection.

In December 2008, Actavis Inc. in the US announced that it reached agreement on a Consent Decree of Permanent Injunction with the Food and Drug Administration (FDA) regarding the company’s Actavis Totowa LLC subsidiary. This Decree only impacted operations at Actavis Totowa’s three facilities in the US: two in Totowa, NJ and one in Little Falls, NJ.

Actavis agreed to not distribute any products from the Actavis Totowa facilities until it certified completion of certain enumerated requirements that demonstrate compliance with FDA’s current good manufacturing practice (cGMP) and has passed follow-up FDA inspections of the facilities. Read more…

Actavis Group, the international generic pharmaceuticals company, today announced the launch of Fluvastatin SR in the UK and the Netherlands. Actavis was first to market in both countries.

Fluvastatin SR extended release tablets from Actavis are the generic equivalent of Novartis’ Luvinsta® SR / Lescol® XL and are available in 80mg tablets in both markets. Fluvastatin SR is used to treat high cholesterol levels in the blood.

Fluvastatin SR tablets are manufactured by Actavis Malta and developed by Actavis’ R&D in Iceland.

This launch was possible after Actavis won a court case in January 2009 in the UK, whereby Novartis’ formulation patent for Fluvastatin SR, which prevented launch of the product until 2017, was revoked. The formulation patent has also been revoked in the Netherlands. Read more…

Realpharmacyrx.com Pharmacy (http://www.realpharmacyrx.com)
RealPharmacyrx-Online.com is a trusted and reliable online pharmacy for brand name and generic prescription drugs at a tremendous savings to thousands of customers worldwide. It is one of the most dedicated sites which provide its customers top quality medicines at the lowest prices online. They offer medication services to customers in various countries. It provides excellent services to its customers and the customers can count on this site which is devoted to their well being. They ensure safe arrival of medicines to your home, office or your post office box.
If a man has early morning erections and can masturbate climax is the cause is probably psychological, which forms the remainder of cases. However, many men suffer from a combination of physical and psychological causes. It is very easy for male impotence to become stressed and dejected on his situation and this makes matters worse. Men are men suffer silently, and they are often too embarrassed or ashamed to talk about a problem to anyone. Erectile dysfunction, sometimes called “impotence,” is the repeated inability to get or keep an erection firm enough for sexual intercourse. The word “impotence” may also be used to describe other problems that interfere with sexual intercourse and reproduction, such as lack of sexual desire and problems with ejaculation or orgasm. Using the term erectile dysfunction makes it clear that those other problems are not involved. But through realpharmacyrx it Can it be treated? 95 percent of sufferers have treatable conditions. Blood flow in penis is the heart of an erection, so the range of treatment options address the effect of blood that the penis tissue. And realpharmacyrx.com carries a number of them, Levitra, Viagra, Cialis and other … (See the Men’s Health Section drop-down box at the top of home page.)

Read more…

Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT™) Signal, announced today the use of the company’s patented Endo-PAT2000 in the Carolinas HealthCare System’s study of the potential benefits of flavonoid supplementation on endothelial function.

The Endo-PAT2000 was used to measure participants’ endothelial function in a study designed to evaluate how flavonoid supplementation can prevent the adverse impact on endothelial function caused by a high-fat meal.

Various foods high in flavonoids such as black tea, dark chocolate, red wine and citrus fruits have been associated with lower risk for cardiovascular disease, and medical research conducted with foods high in flavonoids have demonstrated improvement in endothelial dysfunction, the earliest clinically detectable stage of cardiovascular disease.

Itamar Medical’s Endo-PAT2000 was used to measure endothelial function in 23 healthy volunteers before and after 4 weeks of flavonoid and placebo supplementation. According to Endo-PAT measurements, eating a high-fat meal produced an acute decline in endothelial function for all volunteers before supplementation, and after 4 weeks of placebo supplementation. However, Endo-PAT measurements indicated no similar acute decline in endothelial function from the consumption of a high-fat meal after 4 weeks of flavonoid supplementation. Study results indicate that flavonoid supplementation can reduce the acute Read more…

Celox-A™, the new applicator for penetrating trauma wounds has now obtained a class 3 CE Mark approval allowing use in Europe.

MedTrade, Crewe, UK is proud to announce the European launch at Medica, Dusseldorf (19th -22nd Nov 08) of Celox-A.

Penetrating wounds like shrapnel or knife wounds are very difficult to treat. They can often be lethal. It is extremely difficult to get any blood clotting agent to the real source of bleeding.

Celox™-A’s patented application system now offers a solution, which allows rapid and effective treatment of life threatening bleeding. The applicator is easy and instinctive to use. It allows you to get the Celox™ granules through a small entry wound, directly to the bleeding site in just a few seconds. In clinical testing it has repeatedly shown itself to be able to quickly and reliably stop deep arterial bleeds. Read more…

New analytical and R&D laboratories to expand the research and development efforts for controlled release and other technically difficult generic pharmaceutical products opened in Actavis South Atlantic, a United States division of the international generic pharmaceutical company Actavis.

The labs have been expanded by about 300 sq meters and the new R&D labs have been expanded by about 140 sq meters. The CEO of Actavis Group, Sigurdur Oli Olafsson, participated in the celebration and ribbon cutting ceremony.

Recently launched Actavis South Atlantic products in the United States include Bupropion XL and SR, the generic equivalents of GSK’s Wellbutrin XL® and SR® as well as Nifedipine ER, the generic equivalent of Bayer’s Adalat® CC.

“Actavis in the United States is focused on our vision and commitment to be on the cutting edge of new technology. The expansion of our South Atlantic R&D facility ensures that we remain well-positioned to develop and manufacture XL (extended release) and CR (continuous release) drugs,” said Doug Boothe, Actavis U.S. CEO.

Actavis is one of the leading companies in the U.S. market in the development of controlled release products, with more than EUR 50 million expected to be invested in controlled release development in 2008. Actavis has 13 pending ANDAs for controlled release products with the FDA.

About Actavis Group

Actavis is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries, with 11,000 employees.

CR versions of drugs expand the therapeutic application of products and are highly sought after by branded pharmaceutical companies because of their ability to extend product life cycles. Actavis South Atlantic applies its proprietary technologies to selected high value branded pharmaceuticals and duplicates the release characteristics of the originator drugs in order to bring to market generic versions that can be substituted for these branded products.

Russell Sabella, a former Senior Sales Representative with GlaxoSmithKline in the Bronx, NY has penned down an e-book on the ways to earn a good career in the pharmaceutical industry. The author’s career with GlaxoSmithKline stemmed from April 2004 until June of 2008.

This e-book is a funny, witty and sometimes off the wall memoir which crashes into a “how to” genre for recent college graduates trying to get into the competitive pharmaceutical industry. I Wanna Pharma Job is written to make young people laugh, feel comfortable and understand what it takes to get into pharmaceutical sales. It is a personal account of what the author (Russell Sabella) experienced in his pursuit to get into the industry, and what to expect before you get into the industry.

Read more…

Actavis Group employees from diverse departments from all over the world will be present at this year’s annual CPhI conference, held in Frankfurt, Germany, 30 September to 2 October.

Actavis’ third party sales division, Medis, had its own stand at the CPhI exhibition for 8 years, but shared the floor with Actavis Group last year for the first time. Actavis and Medis employees will take part in the CPhI conference, the world’s leading pharmaceutical trade conference, now in its 19th year.

CPhI Worldwide 2008 presents a truly unique opportunity to exhibit in front of a global contingent of pharmaceutical professionals. Gathering in Frankfurt, this three day event will attract everyone from manufacturers and purchasers of fine chemicals and pharmaceuticals to solution providers, all in search of the latest industry developments.

CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. The first CPhI Worldwide in 1990 attracted 250 visitors for the 16 exhibitors. This year about 24,000 industry professionals are expected, visiting about 1,500 exhibiting companies from more than 125 countries.

For more information about the conference visit www.cphi.com.